Sana Biotechnology, Inc. (NASDAQ:SANA) Given Consensus Recommendation of "Buy" by Brokerages

Key Points

• Sana Biotechnology, Inc. has received a consensus "Buy" rating from analysts, with an average 1-year price target set at $8.00.
• Several institutional investors have significantly increased their stakes in Sana Biotechnology, with the firm now being 88.23% owned by institutional investors.
• As of the latest trading session, Sana Biotechnology's shares opened at $2.98 and have a 52-week low of $1.26 and a high of $7.30.

Shares of Sana Biotechnology, Inc. (NASDAQ:SANA - Get Free Report) have earned a consensus rating of "Buy" from the six research firms that are currently covering the company, MarketBeat Ratings reports. Six equities research analysts have rated the stock with a buy rating. The average 1-year price target among analysts that have issued a report on the stock in the last year is $8.00.

A number of research firms have issued reports on SANA. JMP Securities reissued a "market outperform" rating and issued a $5.00 target price on shares of Sana Biotechnology in a research note on Tuesday, June 24th. Morgan Stanley began coverage on Sana Biotechnology in a research note on Thursday, July 3rd. They issued an "overweight" rating and a $12.00 target price for the company.

Sana Biotechnology Stock Down 0.7%

Shares of Sana Biotechnology stock traded down $0.02 during trading on Friday, reaching $2.96. 3,612,816 shares of the company were exchanged, compared to its average volume of 4,549,232. Sana Biotechnology has a twelve month low of $1.26 and a twelve month high of $7.30. The business has a 50-day moving average price of $3.71 and a 200-day moving average price of $2.70.

Sana Biotechnology (NASDAQ:SANA - Get Free Report) last posted its earnings results on Monday, August 11th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.20) by $0.04. Research analysts predict that Sana Biotechnology will post -1.16 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of SANA. Tower Research Capital LLC TRC boosted its position in shares of Sana Biotechnology by 229.9% during the fourth quarter. Tower Research Capital LLC TRC now owns 15,136 shares of the company's stock worth $25,000 after buying an additional 10,548 shares during the period. Ameriprise Financial Inc. acquired a new position in shares of Sana Biotechnology during the fourth quarter worth about $29,000. Pallas Capital Advisors LLC acquired a new position in shares of Sana Biotechnology during the first quarter worth about $29,000. Nisa Investment Advisors LLC boosted its position in shares of Sana Biotechnology by 673.8% during the second quarter. Nisa Investment Advisors LLC now owns 10,911 shares of the company's stock worth $30,000 after buying an additional 9,501 shares during the period. Finally, Hoey Investments Inc. acquired a new position in shares of Sana Biotechnology during the second quarter worth about $33,000. 88.23% of the stock is owned by institutional investors and hedge funds.

Sana Biotechnology Company Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.